PROSE Treatment in Atypical Ocular Graft-Versus-Host Disease

被引:11
|
作者
Chiu, Gloria B. [1 ]
Theophanous, Christos [1 ]
Irvine, John A. [2 ]
机构
[1] Univ Southern Calif, Keck Sch Med, Dept Ophthalmol, Los Angeles, CA USA
[2] Univ Calif Los Angeles, Doheny Eye Inst, Los Angeles, CA USA
关键词
graft-versus-host disease (GvHD); persistent epithelial defects (PEDs); Prosthetic Replacement of the Ocular Surface Ecosystem (PROSE); scleral lenses; systemic immunosuppression; SYSTEMIC MASTOCYTOSIS; SOLITARY MASTOCYTOMA;
D O I
10.1097/OPX.0000000000001003
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose. To report a case of persistent epithelial defects in a patient with ocular chronic graft-versus-host disease that required coordinated modulation of systemic immunosuppressive treatment and overnight wear of Prosthetic Replacement of the Ocular Surface Ecosystem (BostonSight PROSE, Needham, MA) devices to achieve ocular surface healing. Case Report. The case of a 38-year-old male patient who presented with a 2-year history of ocular chronic graft-versus-host disease, ocular burning, pain, light sensitivity, and a 3-week history of bilateral corneal epithelial defects is presented. Standard therapies and an initial PROSE treatment utilizing customized scleral lenses were unsuccessful in resolving his ocular complications. A second trial of PROSE treatment involving overnight wear of the devices in combination with increased systemic immunosuppressant therapy ultimately allowed ocular surface healing and improved his discomfort, vision, and quality of life. Conclusions. Sight-threatening complications of ocular chronic graft-versus-host disease often require a multidisciplinary approach. Persistent corneal epithelial defects may require increased systemic immunosuppression and extension of PROSE treatment to overnight wear.
引用
收藏
页码:1444 / 1448
页数:5
相关论文
共 50 条
  • [31] Lifitegrast ophthalmic solution for treatment of ocular chronic graft-versus-host disease
    Chhabra, Saurabh
    Jerkins, James H.
    Conto, John E.
    Zellner, Katie
    Shah, Nirav N.
    Hari, Parameswaran N.
    Hamadani, Mehdi
    LEUKEMIA & LYMPHOMA, 2020, 61 (04) : 869 - 874
  • [32] Acute graft-versus-host disease of the lung with atypical presentation
    Peng-Chan Lin
    Liang-Tsai Hsiao
    Po-Min Chen
    International Journal of Hematology, 2006, 84 : 1 - 1
  • [33] THALIDOMIDE FOR TREATMENT OF GRAFT-VERSUS-HOST DISEASE
    VOGELSANG, GB
    HESS, AD
    SANTOS, GW
    BONE MARROW TRANSPLANTATION, 1988, 3 (05) : 393 - 398
  • [34] Ruxolitinib for treatment of Graft-versus-Host Disease
    Krueger, W. H.
    Neumann, T.
    Weigel, M.
    Plis, A.
    Schneidewind, L.
    Vaizian, R.
    Schmidt, C. A.
    ONCOLOGY RESEARCH AND TREATMENT, 2018, 41 : 70 - 71
  • [35] Acute graft-versus-host disease of the lung with atypical presentation
    Lin, Peng-Chan
    Hsiao, Liang-Tsai
    Chen, Po-Min
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2006, 84 (01) : 1 - 1
  • [36] Advances in the treatment of graft-versus-host disease
    Vogelsang, GB
    LEUKEMIA, 2000, 14 (03) : 509 - 510
  • [37] Treatment options for graft-versus-host disease
    Hilgendorf, Inken
    Wolff, Daniel
    EXPERT OPINION ON ORPHAN DRUGS, 2013, 1 (09): : 731 - 743
  • [38] The Treatment of Chronic Graft-Versus-Host Disease
    Wolff, Daniel
    Bertz, Hartmut
    Greinix, Hildegard
    Lawitschka, Anita
    Halter, Joerg
    Holler, Ernst
    DEUTSCHES ARZTEBLATT INTERNATIONAL, 2011, 108 (43): : 732 - I
  • [39] THALIDOMIDE IN THE TREATMENT OF GRAFT-VERSUS-HOST DISEASE
    HENEY, D
    BAILEY, CC
    LEWIS, IJ
    BIOMEDICINE & PHARMACOTHERAPY, 1990, 44 (04) : 199 - 204
  • [40] Pathophysiology and treatment of graft-versus-host disease
    Flowers, MED
    Kansu, E
    Sullivan, KM
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 1999, 13 (05) : 1091 - +